In a previous report, we described that tumor necrosis factor (TNF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) synergistically enhanced the development of dendritic cell (DC) progeny from early stem cells and that there is a common monocyte-DC progenitor cell. Low levels of DC were obtained with GM-CSF alone, and TNF by itself failed to induce stem cell development. Here, we investigate mechanisms by which TNF and GM-CSF institute increases in DC, and how these same molecules support later stages of DC differentiation. We show that TNF is required as the first signal, that there is upregulation of GM-CSF receptors (GM-CSFRs), and that TNF inhibits the differentiation of colony-forming units-granulocyte. High levels of GM-CSFR were always associated with conditions yielding a large number of DC, and a kinetic analysis showed a close ontogenic relationship between HE DEVELOPMENT OF differentiated progeny from T hematopoietic stem cells is a complex multistep process involving the positive and negative regulatory actions of ~ytokines.'-~ In the erythroid and myeloid lineages, the differentiation of common progenitors may be initiated by nonlineage restricted cytokines such as interleukin-1 (IL-I), IL-3, and stem cell factor (SCF).1-7 Ultimate development and enhancement of mature erythroid, monocytic, and granulocytic progeny occurs in the presence of erythropoietin, monocyte colony-stimulating factor (M-CSF), and granulocyte colony-stimulating factor (G-CSF), respectively, which are lineage-restricted (late acting) cytokines.'"lP6-* The development of restricted progeny can also be achieved by the appropriate combination of multilineage cytokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-3) with other regulatory proteins. In these cases, enhanced colony formation is not supported by either growth factor alone. The development of eosinophils with GM-CSF and IL-5,1-3,9 and of basophils with GM-CSF, IL-3, and IL-4 are specific examples ofthese synergistic interactions. 1~4~0 We and others have recently shown that the dendritic cell pathway can be enhanced by the synergistic actions of two pleiotropic c y t o k i n e~.~'~~~ We noted that purified CD34' stem cells from neonatal cord blood treated with tumor necrosis factor (TNF) and GM-CSF underwent proliferative responses and matured into cells exhibiting the morphologic and functional characteristics of dendritic cells." The simultaneous development of macrophages also occurred in these cultures. The presence of colonies containing both macrophages and dendritic cells (DCs) showed a common monocyte-DC progenitor and the close ontogenic relationship between these two cell types. GM-CSF was the only cytokine tested that by itself, induced low levels of DCs, and TNF in the absence of GM-CSF was incapable of inducing stem cell development.
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Investigators studying the capacity of TNF to enhance GM-CSF-induced proliferation of AML cells determined that TNF promoted upregulation of GM-CSF receptors (GM-CSFRs) and suggested this as a mechanism for TNF DC and GM-CSFR levels. The addition of anti-GM-CSF or anti-TNF antibodies blocked synergistic responses related to DC development, including high levels of GM-CSFRs. Anti-GM-CSF was the most potent inhibitor of proliferation (80%) and macrophage, DC, and polymorphonuclear (PMN) cell development. With polyclonal anti-TNF, inhibition was less (35%). and there was a shift from myelomonocytic and DC to PMN progeny. Our results support the concept that receptor upregulation is an important mechanism for growth factor synergy. Our data also indicate that the opposing effects of TNF on hematopoiesis contribute to the selection of the DC pathway and emphasize the importance of GM-CSFRs not only in initiating DC development, but also in controlling DC viability and function. 0 1993 by The American Society of Hematology.
and GM-CSF synergy.I4 Other reports on the potentiation effects of TNF on the monocytic pathway have indicated that downregulation of the colony-forming unit-granulocyte (CFU-G) pathway leads to subsequent enhancement of the colony-forming unit-monocyte (CFU-M) pathway." In this study, we investigate whether TNF and GM-CSF-amplified DC development involves either of these mechanisms. Our results support that, in the least, both these mechanisms are involved. In addition, we establish that GM-CSFRs are not only upregulated during early phases of DC development but are maintained at high levels during the entire DC pathway. Finally, the effects of antibodies to GM-CSF and TNF in blocking DC development are discussed.
MATERIALS AND METHODS
Enrichment of neonatal cord blood-derived stem cells. Neonatal cord blood was collected into sterile heparinized containers from healthy full-term infants, according to institutional guidelines, at the time of repeat caesarean sections. The blood was diluted and layered over a pyrogen-poor Lymphoprep (Nyegaard, Norway) gradient for the isolation of mononuclear cells (MNCs). MNCs were then placed on two consecutive nylon wool columns (NWXZ) for the enrichment of nonadherent stem cells as previously deThis procedure results in fourfold to fivefold enrichment of CD34+ cells and the complete removal of mature hematopoietic elements except T and natural killer (NK) cells, as previously shown.
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Subsequent purification of CD34+ cells used either antibody and complement (C) depletion of T and NK cells, or positive selection using immunomagnetic beads. For antibody and C depletion, NWx2 nonadherent cells were incubated with monoclonal antibodies (MoAbs) to T-cell (CD3, OKT3) and NK-cell (CD57) antigens (American Type Culture Collection, Rockville, MD) for 40 minutes at 4"C, washed twice in RPMI 1640, incubated with rabbit C (1:15) for 45 minutes at 3 7 T , and then washed twice again. This procedure resultsin a cell population (NWX2-T, -NK) with a viability ofgreater than 90% and containing -20% CD34+ cells. Controls consisted of C treatment in the absence of MoAbs. For positive selection, NWX2 cells were incubated with MoAb to CD34 (Becton Dickinson, Mountain View, CA) for 40 minutes at 4"C, washed twice, and then reacted with antimouse IgG linked to immunomagnetic beads (Dynabeads; Dynal Inc, Great Neck, NY) at a bead to cell ratio of 5: 1. After 50 minutes, cells expressing CD34 antigens were positively selected using a magnetic cell concentrator (Dynal MPC-1). The beads were removed from the cells using Detachabead (Dynal), as suggested. The final cell population after this treatment consisted of cells that were greater than 90% CD34' and greater than 95% viable, as determined by trypan blue dye exclusion.
Culture conditions for DCgrowth. CD34'-enriched cell populations and pure CD34+ cells were adjusted to 0.5 to 1 .O X IO6 and 1 to 2.5 X IO5 cells/mL, respectively, in RPMI 1640 medium containing 2 mmol/L L-glutamine, 10 mmol/L HEPES, 50 IU/mL penicillin, 50 pg/mL streptomycin, and 5% pooled normal human sera (NHS/RPMI). This concentration of NHS does not sustain stem cell proliferation, as previously shown." Recombinant TNF-a (Knoll Pharmaceuticals, Whippany, NJ) was added to stem cell populations in NHS/RPMI at 500 U/mL; recombinant GM-CSF (Genzyme, Boston, MA) was added at 100 U/mL. The optimal concentration for each factor was determined as previously described." Cells were incubated at 37°C in a 5% C 0 2 humidified incubator in either Teflon culture vials (Scientific Specialties Service, Randalstown, MD) or 24-well tissue culture plates. Cells cultured in suspension (Teflon), when transferred to adherent conditions, exhibited characteristics identical to those grown under adherent conditions at the onset of the culture period. The endotoxin levels were controlled, as previously described.16
In situ analysis showed that cells exhibiting dendritic cell morphology were positive for class 11 major histocompatibility complex (MHC) antigens but CD14-, did not exhibit nonspecific esterase activity, and were incapable of phagocytosing latex bead particles, as previously described."
Sequential studies. To assess whether TNF or GM-CSF was required as a first signal in TNF + GM-CSF synergy, cells were preincubated with either recombinant TNF-a (Knoll Pharmaceuticals) at 500 U/mL or recombinant GM-CSF (Genzyme) at 100 U/mL for I, 3,5, and 7 days. At each time point, cells were removed from culture, washed to remove any endogenous cytokines, and the second cytokine was added. After further incubation, proliferative and morphologic analyses were performed. Proliferative capacity of cultured cells. Cells were analyzed for proliferation by the uptake of [3H] thymidine and by manual cell counts using a hemacytometer (Improved Neubauer; Fischer Scientific, Pittsburgh, PA). For thymidine uptake, 0.5 pCi of [3H] thymidine (specific activity, 25 Ci/mmol/L; Amersham, Arlington, IL) was added to 100 p L of cells in 96-well microtiter plates. After 5 hours of incubation, cells were harvested using an automated sample harvester and counted in a liquid scintillation counter. Results are expressed as the mean of triplicate counts; the standard error was I 15% in all experiments.
The effect of antibodies to TNF and GMBlocking antibodies.
CSF in blocking DC development was investigated by adding one of these reagents to stem cell populations containing TNF and GM-CSF at the onset ofthe culture period. Mouse antihuman GM-CSF MoAb antibody (Genzyme) was tested at concentrations of 10 and 20 pg/mL. Polyclonal antihuman TNF-a (Genzyme) was tested at doses of 5, 10, and 25 pg/mL. MoAbantihuman TNF-CY (UBI, Lake Placid, NY) was analyzed at 50, 100, and 500 ng/mL. Both antibodies were functionally defined in bioassays, and were effective at neutralizing TNF-mediated cytotoxicity, but no studies on the effects of TNF regulation of hematopoiesis were reported. The MoAb did not block the proliferative capacity of the stem cells or their pattern of differentiation, whereas the polyclonal did. This suggests that different epitopes on TNF regulate cytotoxic and hematopoietic functions. Nonspecific effects were addressed by adding isotypic control antibodies (IgG, IgM; Coulter Immunology, Hialeah, FL) at saturating concentrations instead of anti-TNF or GM-CSF.
GM-CSFR ligand studies. GM-CSFRs were detected using a GM-CSFR kit purchased from R&D Systems (Minneapolis, MN). This strategy uses the binding of ligand to a fluorochrome to facilitate the detection of cell surface receptors by flow cytometric analy-S~S . ' "~~ In this particular application, cell populations expressing GM-CSFRs are identified and increasing intensity of fluorescence correlates with increasing GM-CSFR levels.'' Assays were performed according to the manufacturer's instructions. Briefly, 10 pL (0.1 fig) of biotin-labeled recombinant GM-CSF was added to approximately 1 X IO5 cells for 1 hour at 4°C. Cells were then washed twice, 10 pL (0.1 pg) of avidin-fluorescein isothiocyanate (FITC) was added, and the suspension was incubated for an additional 30 minutes at 4°C and was protected from light. Cells were again washed twice, fixed in 10% buffered formalin for 5 minutes at room temperature, and washed in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA), 0.1% sodium azide (PBS/BSA/azide) in preparation for flow cytometry (FACScan; Becton Dickinson). Calibration of the instrument was performed with Calbrite beads (Becton Dickinson). A total of 10,000 events was analyzed using 488 nm wavelength excitation. Data were analyzed using a LYSYS software program (Becton Dickinson). Debris and dead cells were omitted on the basis of forward and right angle scatter. Controls for nonspecific fluorescence consisted of treating paired samples from each culture condition with avidin-FITC alone.
Receptor blocking studies. Specificity of the biotin-labeled GM-CSF binding to cell surface GM-CSF receptors was established in competition assays as follows: 1.0 X IO5 CD34' stem cells were incubated with 5 p g (50-fold molar excess) of human recombinant GM-CSF (R&D Systems) at 4°C with frequent gentle resuspension. After 30 minutes, 0.1 pg of biotin-conjugated GM-CSF was added to the tube, the suspension was mixed, and the GM-CSFR assay was completed as indicated above.
Student's t-test analysis was performed using a Crunch Interactive Statistical Package (CRISP; Crunch Software Corp, San Francisco, CA).
Statistics.
RESULTS
Sequential studies. We sought to determine whether TNF or GM-CSF was the first cytokine required in signalling synergistic dendritic cell development. Figure 1 depicts cells pretreated with TNF for 1 to 7 days before the addition of GM-CSF. Cells cultured with TNF for up to 3 days with subsequent addition ofGM-CSFexhibited DC content similar (25% to 40%) to that obtained when GM-CSF and TNF were added simultaneously at day 0 (Fig l A , B, and D) . After day 5, DC content decreased dramatically (Fig 1C) . In fact, the sequential addition of GM-CSF to cells pretreated with TNF for 7 days (Fig IC) yielded little stem cell development and a population of cells that resembled treatment with TNF alone.'' The reciprocal experiment, involving pretreatment with GM-CSF followed by the addition of TNF at various periods (I. 3, 5, and 7 days), did not show increases in DC content other than those noted with GM-CSF alone (I 10%) (Fig I E) . There was no stem cell development in the presence of 5% NHS/RPMI alone.
These experiments indicate that TNF. not GM-CSF, is required as the first signal and that there is sensitivity to the secondary effects of GM-CSF for up to 72 hours. Other investigators found that TNF/GM-CSF synergistic effects on CD34+ human bone marrow cells were restricted to the early addition of TNF. in support of these observations.12
Prolifcrati\v rcJ,spon.ses associated with TNF or GM-CSF pretreatment. In Fig 2, we compare thymidine uptake in stem cells preincubated with either TNF or GM-CSF for 72 hours followed by the addition of GM-CSF and TNF, respectively. On day 7. marked proliferation was noted in cultures pretreated with TNF but not in those pretreated with GM-CSF. In the two experiments shown, increases CSF-induced stem cell proliferation (measured by thymidine uptake) when anti-GM-CSF is present at the onset of the culture period (P = .0004). Manual cell counts also showed that these cultures contained approximately onethird as many cells as cultures treated with TNF + GM-CSF (P = .015) (Fig 3B) . When analyzed under phase microscopy, cultures containing anti-GM-CSF from the beginning (day 0) were sparse, with few DCs, compared with cultures treated with GM-CSF + TNF alone (Fig 4A) .
Interestingly, addition of anti-GM-CSF later in culture (day 10) resulted in the abrogation of DC morphology within 48 hours (Fig 4D) . These results show that DC development can be blocked either at the progenitor cell level or after differentiation events have been induced by the same agent.
Addition of polyclonal anti-TNF interfered with the proliferative capacity of TNF + GM-CSF-treated cells (P =
.0025), albeit not as intensely as anti-GM-CSF (35% v SO%, respectively; Fig 3) . In contrast, MoAb anti-TNF added at the onset of the culture period did not interfere with stem cell proliferation, even when tested at 500 ng/mL. Isotypic controls (nonimmune mouse IgG and IgM) did not impede proliferation, nor progeny outcome (Fig 4C and Table l) , excluding nonspecific inhibition.
Even though anti-GM-CSF is a potent inhibitor of stem cell proliferation, some progeny developed in the cultures. As indicated in Table 1 and Fig 5B, large MNC and polymorphonuclear cells (PMN) are the main components (58% :A 42%, respectively). Treatment with polyclonal anti-TNF resulted in a more selective lineage outcome. Approximately 75% of the progeny in cultures treated with polyclonal antibody at 5 or IO pg/mL was PMN. Of these 75% the majority were basophils (Fig 5A) , with the remaining 24% being monocytes; very few DCs were present ( Table 1) .
Expression of GM-CSFRs. Temporal analysis showed early increases and the persistence of GM-CSFRs throughout the culture period when stem cells were treated with TNF + GM-CSF (Fig 6) . The combination of TNF + GM-CSF yielded at least threefold increases in GM-CSFR levels by day 2 (NHS v TNF + GM-CSF, P = .007). In contrast, after 2 days of in vitro culture with GM-CSF or TNF, GMCSFRs were not significantly increased beyond growth in 5% NHS/RPMI (Fig 6) . Although on the rise by day 7, there were still no significant increases in GM-CSFR levels between growth in GM-CSF, TNF, or NHS/RPMI (P > .05).
Receptor levels in TNF + GM-CSF-versus GM-CSFtreated day-7 cultures were significantly increased (P = .03).
Very high levels of GM-CSFRs were noted around day 10 in TNF + GM-CSF-treated cultures (TNF + GM-CSF v GM-CSF, TNF, NHS, P < . O 12) . Towards the end of the culture period, receptor levels declined, but were still higher in GM-CSF and TNF + GM-CSF than in TNF or NHS cultures (the differences were not statistically significant).
Early GM-CSFR upregulation did not result from GM-CSF treatment alone (Fig 6) . The only significant increases in GM-CSFR levels with GM-CSF treatment were noted on day 10 (v NHS cultures, P = .02). At this point in culture, differentiation events are complete and the cultures contain mostly monocyte-macrophages and few DCs."
The above results were obtained using cultures enriched over GM-CSF pretreatment were 2.6-to 9.0-fold (P < .04) (Fig 2B and A, respectively) . Uptake in NHS controls was 5300 cpm. Microscopic examination showed DC content similar to that observed with the simultaneous addition of TNF + GM-CSF (Fig ID) . Moreover, the proliferative capacity ofthe cells pretreated with TNF approximated that of simultaneous addition of TNF and GM-CSF at the onset of culture (Fig 2B) . Increases in cell number in the TNF-pretreated cultures were confirmed by manual cell counts (data not shown).
Cells pretreated with GM-CSF followed by TNF exhibited a marked inhibition in proliferation on day 7 (Fig 2) . The effect was reversible, as noted by the rebound on day 10 (Fig2A and B) . Microscopic examination, Wright stain analysis, and assessment of nonspecific esterase activity showed that on day 10 most cells were macrophages, with some granulocytes present, and that there were no synergistic increases in DCs. In contrast, similar examination of TNF pretreated cells on day 10 showed synergistic increases in the number of DCs.
Others have shown that TNF has both positive and negative effects on h e m a t o p o i e~i s , '~~~'~~~ in support of these results.
Efect of anti-TNF and anti-GM-CSF antibodies on DC development. Figure 3A Fig 7A. This indicates that the highest levels of GM-CSFRs are not exhibited on larger macrophages, consistent with our findings that GM-CSF treatment alone, while producing mostly macrophage progeny, does not elicit highest levels of GM-CSFR (Fig 6) . Finally, the effect of anti-TNF and anti-GM-CSF on the expression of GM-CSFR was also investigated. As summarized in Table 2 , the levels of receptor correlated closely with the effects of the particular antibody on the DC pathway. Thus, anti-GM-CSF and polyclonal anti-TNF, which severely hampered DC development (Table 1 and Fig 4) , also inhibited the expression of GM-CSFR. Conversely, MoAb anti-TNF, which had no effect on the DC pathway, did not interfere with GM-CSFR levels.
Specificity ofthe GM-CSFR reaction. Competition studies showed the specificity of the reagents used to detect GM-CSF receptors. Pretreatment of TNF + GM-CSF cultures (derived from pure CD34+ stem cells) with a 50-fold molar excess of unbound GM-CSF resulted in approximately 40% inhibition of the binding reaction, as shown in Fig 7B. 
DISCUSSION
In this report, we provide insight into how TNF and GM-CSF initiate the generation of DCs from early stem cells and how these same molecules are involved in maintaining mature DC progeny. Our studies support the developing con- Culture   Fig 6. GM-CSFR content was assessed on stem cells cultured in NHS/RPMI without added cytokines (w), NHS/RPMI with either 500 U/mL TNF (0) or 100 U/mL GM-CSF (A). or NHS/RPMI with 500 U/mL TNF and 100 U/mL GM-CSF (A) during the entire period corresponding to DC development. Values depict the mean fluorescence intensity after negative controls were subtracted. For all curves, each time point represents the mean of three to five experiments.
cept that receptor upregulation is an important mechanism for growth factor ~y n e r g y . '~,~~,~~ We establish, with respect to synergistic increases of the monocyte-DC pathway promoted by TNF + GM-CSF that (1) TNF is required as the first signal, (2) there is early upregulation of GM-CSFR, and (3) high levels of GM-CSFR are maintained in close association with DC development. We also discuss how the DC pathway can be affected by antibody treatment directed toward the growth components.
There is a window of sensitivity related to the priming effects of TNF. Stem cells pretreated with TNF for up to 3 days responded to the secondary signalling effects of GM-CSF to generate increases in DCs. After 5 days of TNF pretreatment, no increases in DCs were observed with the sequential addition of GM-CSF, and the cells resembled those treated with TNF alone (Fig 1) . Examination ofthe proliferative data related to TNF and GM-CSF pretreatment exposed that TNF can exert both positive and negative effects on hematopoiesis (Fig 2) . Positive effects on the DC pathway were observed when stem cells were pretreated with TNF for 72 hours and then incubated with GM-CSF. Results were consistent with the proliferative effects induced by the simultaneous addition of TNF and GM-CSF. Marked inhibition of proliferation occurred with the reverse treatment, ie, when cells were first pretreated with GM-CSF and then TNF was added. Temporal analysis of this response showed that inhibition occurred after the cells had been subjected to the differentiating effects of GM-CSF, and that the inhibition was reversible (Fig 2) . We conclude that the effects of TNF on early and late progenitor cells may be completely opposite, which is consistent with recent observations.21-26 Because the great majority of the progeny arising with GM-CSF pretreatment was myelomonocytic, we are also in agreement that TNF exerts negative effects by inducing downregulation of CFU-G. L5,2L,22
Several attempts were made to manipulate the DC pathway with antibodies to TNF or GM-CSF. Anti-GM-CSF was the most potent inhibitor of TNF + GM-CSF synergy.
In the presence of this antibody, proliferative events were reduced by -80% and DC development was greatly affected (Fig 3 and Table I ). There appeared to be no selective inhibition of the granulocytic and monocytic pathways, because the limited progeny arising in the presence of this antibody consisted of similar proportions of PMN and monocyte-macrophages (Table 1) . Addition of anti-GM-CSF to mature DC progeny resulted in the abrogation of DC morphology within 48 hours (Fig 4D) .
We were able to inhibit TNF + GM-CSF synergy with a polyclonal anti-TNF that involved at least two different mechanisms. One effect was a shift from myelomonocytic to PMN development ( Table 1 and Fig 5A) . The other effect concerned the DC pathway, as noted by the few DCs present. We speculate that the polyclonal anti-TNF neutralizes the TNF-mediated downregulation of CFU-G, and that the effects on DC development are because of the prevention of TNF binding to cell surface TNF receptors to signal upregulation of GM-CSFR.
The biologic significance of GM-CSFR modulation as a mechanism for DC cell growth regulation is central to this study. Our report upholds that TNF-GM-CSF synergy results in the upregulation of GM-CSFR on stem cells committed to the monocyte-DC pathway during early phases DC development and that GM-CSF alone does not induce this effect. These results are compatible with reports concerning GM-CSFR levels on AML cells.14 The highest levels of GM-CSFR were always associated with conditions yielding a large number of DC progeny (TNF + GM-CSF). At the time points tested, TNF and NHS treatment (which does not induce DC development) elicited the lowest levels of GM-CSFR. GM-CSF-treated cultures, which contained mostly monocyte-macrophages and -10% DC, followed in GM-CSFR content. It is possible that the increased GM-CSFR level on day 10 reflects the DC content in these cultures. However, there were no significant increases in GM-CSFR before day 10, supporting the idea that GM-CSF alone does not upregulate its own recepto9' and that the increases noted on day IO may be due to the effects of secondary cytokines. 25 We previously reported that proliferative responses associated with the development of DC from TNF + GM-CSF -treated CD34' stem cells increased precipitously after 2 days in culture. Peak proliferation, occurring around days 7 to 10, correlated with peak DC content, and declining proliferative events (-day 14) correlated with loss of DC content." We show here that GM-CSFRs follow the same kinetic pattern, ie, precipitous increases in GM-CSFR levels occur after day 2, peak GM-CSFR levels are noted around day 10, and declining levels around day 14. We also show that, when development of DCs is impaired with polyclonal anti-TNF or anti-GM-CSF, there is a corresponding decline in GM-CSFRs ( our observations and credence to the significance of GMCSFRs in the DC lineage.30 With respect to the early events associated with GM-CSFR upregulation, it is possible that TNF increases levels of GM-CSFR on stem cells to a threshold required for synergy or that TNF recruits additional cells (perhaps subsets) into the proliferative c~m p a r t m e n t . '~*~~ Because rapid (by day 2) upregulation of GM-CSFR preceded differentiation events and significant increases in proliferation, we favor the idea that GM-CSFR levels are increased to threshold levels on existing stem cells. Previous investigators have established that the effects of TNF on GM-CSFR levels is dependent on protein synthesis and that GM-CSFR are synthesized de n 0~0 . l~ However, it is also possible that the requirement for protein synthesis reflects the production of other, as yet unidentified, secondary factors that are important for early DC development.
GM-CSF and TNF both enhance the survival of mature DC in ~i t r o .~' .~' In addition, these cytokines induce each others production, especially by monocyte-macrophages.'~~.~~ Because DC and monocyte-macrophage development occurs in parallel from a common precursor,''J2,34 we propose that a cytokine loop involving TNF, GM-CSF, DCs, and monocyte-macrophages is a mechanism whereby high levels of GM-CSFRs are maintained during subsequent DC development. Because GM-CSFRs are not usually upregulated by TNF on specialized p r~g e n y , '~ this mechanism would be distinctive to the DC lineage. GM-CSF also induces class I1 MHC e x p r e s s i~n ,~~~. '~ which is crucial to the antigen presenting functions of DCs. Other biologic significance of high GM-CSFR levels may include responding to the chemotactic influences of GM-CSF. 34335 Manipulation of the DC pathway such as we describe may be clinically useful in either augmenting DC content in For personal use only. on October 25, 2017. by guest www.bloodjournal.org From 
